BioLineRx reports $4.3 million Q2 loss

• BioLineRx reported a second quarter 2026 net loss of $4.3 million, compared with $3.9 million a year earlier.
• The company held $13.1 million in cash and short-term deposits as of June 30, 2026, with runway expected into the first half of 2027.
• BioLineRx continued dosing patients in its Phase 1/2a GLIX1 study for glioblastoma.

BioLineRx (NASDAQ:BLRX) reported second quarter 2026 results with royalty revenue of $0.3 million and a net loss of $4.3 million, compared with a net loss of $3.9 million in the prior-year period.

The results reflected higher operating expenses as the company advanced its clinical pipeline, with research and development expenses increasing to $2.9 million and general and administrative expenses reaching $0.9 million.

BioLineRx said royalty revenue was mainly generated from APHEXDA sales of $1.6 million, while the company’s second planned cohort in the Phase 1/2a GLIX1 glioblastoma study is dosing and a third cohort is expected to begin in September.

The company reported cash, cash equivalents, and short-term deposits of $13.1 million as of June 30, 2026.

BioLineRx develops therapies for cancer and other serious medical conditions, with its current pipeline focused on oncology programs including GLIX1 for glioblastoma.

The company said a $3.75 million equity offering signed on August 27, 2026 is expected to close around August 31, 2026, while additional preclinical data and conference presentations are planned for its oncology programs.